Effectiveness of indapamide versus enalapril as second-step therapy of systemic hypertension

Richard Ames; George Griffing; Thomas Marbury; Eugene Miller; James Schoenberger; Bruce Glenn; Vincent Benn; Donna Wilkinson

doi:10.1016/0002-9149(92)91319-Y

Effectiveness of indapamide versus enalapril as second-step therapy of systemic hypertension

Richard Ames
, George Griffing
, Thomas Marbury
, Eugene Miller
, James Schoenberger
, Bruce Glenn
, Vincent Benn
, Donna Wilkinson

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	267-270
Number of pages	4
Journal	American Journal of Cardiology
Volume	69
Issue number	3
DOIs	https://doi.org/10.1016/0002-9149(92)91319-Y
State	Published - 15 Jan 1992
Externally published	Yes

Access to Document

10.1016/0002-9149(92)91319-Y

Cite this

@article{e6f2919cd98547a79ed8e95d873311e1,

title = "Effectiveness of indapamide versus enalapril as second-step therapy of systemic hypertension",

author = "Richard Ames and George Griffing and Thomas Marbury and Eugene Miller and James Schoenberger and Bruce Glenn and Vincent Benn and Donna Wilkinson",

note = "Funding Information: This was a prospective randomized, double-blind, placebo-controlled parallel study of indapamide as add-on therapy in comparison with upward titration of enalapril in mild to moderate hypertension. Patients remaining hypertensive after receiving enalapril (5 mgjday) were randomized to supplemental treatment with an additional 5 mg of enalapril, indapamide (2.5 mglday) or placebo. Ambulatory patients with a history of hypertension were recruited by 5 investigators who used a common protocol. The patients were men and women aged between 21 and 75 years who were free of clinically evident concomitant disease. Patients were also excluded for obesity or use of other drug treatments including insulin, lithium and nonsteroidal antiinflammatory drugs. After written consent was signed, patients discontinued taking any prior antihypertensive drug treatment. Placebo capsules were given in open fashion during a 3-week washout period. At the end of the placebo period, patients whose supine diastolic blood pressure was between 95 and I I5 mg Hg were given enalapril in a dose of From Columbia University, College of Physicians and Surgeons, and St. Luke\&Roosevelt Hospital Center, 428 West 59th Street, New York, New York 10019. This report was supported by a grant from Rhone Poulenc Rarer, Inc., Fort Washington, Pennsylvania. Manuscript received January 3, 1991; revised manuscript received and accepted August 30, 199 1..",

year = "1992",

month = jan,

day = "15",

doi = "10.1016/0002-9149(92)91319-Y",

language = "English",

volume = "69",

pages = "267--270",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Effectiveness of indapamide versus enalapril as second-step therapy of systemic hypertension

AU - Ames, Richard

AU - Griffing, George

AU - Marbury, Thomas

AU - Miller, Eugene

AU - Schoenberger, James

AU - Glenn, Bruce

AU - Benn, Vincent

AU - Wilkinson, Donna

N1 - Funding Information: This was a prospective randomized, double-blind, placebo-controlled parallel study of indapamide as add-on therapy in comparison with upward titration of enalapril in mild to moderate hypertension. Patients remaining hypertensive after receiving enalapril (5 mgjday) were randomized to supplemental treatment with an additional 5 mg of enalapril, indapamide (2.5 mglday) or placebo. Ambulatory patients with a history of hypertension were recruited by 5 investigators who used a common protocol. The patients were men and women aged between 21 and 75 years who were free of clinically evident concomitant disease. Patients were also excluded for obesity or use of other drug treatments including insulin, lithium and nonsteroidal antiinflammatory drugs. After written consent was signed, patients discontinued taking any prior antihypertensive drug treatment. Placebo capsules were given in open fashion during a 3-week washout period. At the end of the placebo period, patients whose supine diastolic blood pressure was between 95 and I I5 mg Hg were given enalapril in a dose of From Columbia University, College of Physicians and Surgeons, and St. Luke&Roosevelt Hospital Center, 428 West 59th Street, New York, New York 10019. This report was supported by a grant from Rhone Poulenc Rarer, Inc., Fort Washington, Pennsylvania. Manuscript received January 3, 1991; revised manuscript received and accepted August 30, 199 1..

PY - 1992/1/15

Y1 - 1992/1/15

UR - https://www.scopus.com/pages/publications/0026573112

U2 - 10.1016/0002-9149(92)91319-Y

DO - 10.1016/0002-9149(92)91319-Y

M3 - Article

C2 - 1731472

AN - SCOPUS:0026573112

SN - 0002-9149

VL - 69

SP - 267

EP - 270

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3

ER -